Anti-inflammatory diets & mental health

The effects of anti-inflammatory diet alone or in combination with acupuncture on mental health, advanced glycation end products (AGEs), anthropometric indices and metabolic status in diabetic patients with depression: A randomized, controlled clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110314006065N3

Enrollment

Registered

2021-10-31

Start date

2021-10-24

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: An individualized anti-inflammatory diet with acupuncture therapy. All three groups will receive common treatment (medications, weight-loss diet in overweight and obese subjects, healt

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Suffering from type 2 diabetes mellitus for more than 6 months. taking oral anti-diabetic medications suffering from mild-to-moderate depression

Exclusion criteria

Exclusion criteria: injection of insulin or liraglutide taking medicinal herbs or herbal medicine, antibiotics, antioxidant supplements (multivitamins & minerals, vitamin E, vitamin C, Zinc), suffering from severe depression, having chronic heart -vascular diseases, severe depression, chronic liver chronic liver and kidney disease, uncontrolled thyroid and any other diabetes complications leads to inflammatory and oxidative conditions, other types of diabetes taking psychiatry medications. Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: Baseline, after 8 weeks of the intervention (At the end of the intervention). Method of measurement: Montgomery-Asberg Depression Rating Scale (MADRS).;Fat mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.;Fat free mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.;HbA1c. Timepoint: Baseline, At the end of the intervention. Method of measurement: Chromatography.	—

Measure

Time frame

Depression. Timepoint: Baseline, after 8 weeks of the intervention (At the end of the intervention). Method of measurement: Montgomery-Asberg Depression Rating Scale (MADRS).;Fat mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.;Fat free mass. Timepoint: Baseline, after 4 weeks of intervention and At the end of the intervention. Method of measurement: Bio-Electrical Impedance Analysis.;HbA1c. Timepoint: Baseline, At the end of the intervention. Method of measurement: Chromatography.

—

Secondary

Measure	Time frame
Advanced glycation end products. Timepoint: Baseline, At the end of the intervention. Method of measurement: ELISA kit.;FBS. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;Total cholesterol. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;Low-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;High-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;High-sensitivity C-reactive protein. Timepoint: Baseline, At the end of the intervention. Method of measurement: ELISA kit.	—

Measure

Time frame

Advanced glycation end products. Timepoint: Baseline, At the end of the intervention. Method of measurement: ELISA kit.;FBS. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;Total cholesterol. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;Low-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;High-density lipoprotein. Timepoint: Baseline, At the end of the intervention. Method of measurement: Autoanalyzer.;High-sensitivity C-reactive protein. Timepoint: Baseline, At the end of the intervention. Method of measurement: ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazli Namazi

Tehran University of Medical Sciences

nazli.namazi@yahoo.com+98 21 8863 1298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026